Prostate Small Cell Carcinoma Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0082092 (Prostate Small Cell Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03582475Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateTreatment